Best eQMS for Biotech — Cell + Gene Therapy, Biologics, Vaccines

Biotech adds biotech-specific frameworks on top of pharma cGMP: ICH Q5A-Q5E (viral safety, genetic stability, cell substrates, derivation, comparability), ICH Q6B (specifications for biotech products), FDA 21 CFR Part 211 (cGMP), Part 600/610 (biologics), Part 1271 (HCT/Ps for cell + tissue), EU GMP Annex 11, EU GMP Annex 1 (sterile manufacturing — 2022 revision), Annex 2 (biological products), Part 11 (electronic records). Plus ICH Q9 risk + Q10 PQS + GAMP 5 + ALCOA+ shared with pharma. The eQMS must be validated to GAMP 5 Cat 4 with ICH Q5-aligned product records.

Cell + gene therapies (autologous, allogeneic, viral vector, gene editing) introduce quality challenges that traditional pharma rarely faces: patient-specific batches (autologous CAR-T), short shelf life (hours to days), chain-of-identity / chain-of-custody tracking, vein-to-vein traceability, donor screening, viral safety (ICH Q5A), genetic stability (ICH Q5B). The eQMS must support per-patient batch records, real-time release where applicable, and integration with apheresis / cell processing / cryopreservation systems. Most eQMS vendors handle the QMS layer; cell + gene specifics require integration with specialised CGT platforms.

EU GMP Annex 1 (2022 revision, effective 2023-08) governs sterile manufacturing for pharmaceuticals and biologics. Key changes: explicit Contamination Control Strategy (CCS) requirement; QRM-based approach to all sterile operations; barrier-technology preference (RABS, isolators); enhanced environmental monitoring expectations; explicit data integrity requirements throughout. Biotech sterile manufacturers must update their QMS to evidence CCS, environmental monitoring trending, and risk-based deviation handling. The eQMS Risk and Events modules support the documented CCS lifecycle.

Core: Document Control (controlled SOPs, batch records, master batch records, specifications, analytical methods, cell line / banking records); CAPA (deviation investigation including viral / genetic / sterility deviations); Audits (internal, external supplier, regulatory inspection); Change Control (per-product, per-cell-line impact assessment); Risk Management (ICH Q9 + ICH Q5A-aligned biotech risk); Training / LMS (GMP, biosafety, sterile manufacturing); Events (out-of-specification, environmental excursions, sterility failures, viral safety deviations, complaints). Plus integrations to ERP, LIMS, MES (where applicable), cell-processing / apheresis platforms (CGT).

ICH Q5A (Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin) requires source materials qualification, cell-line viral testing, in-process viral monitoring, and viral clearance validation. The eQMS supports this by maintaining cell-bank records (Master Cell Bank, Working Cell Bank) under document control, viral safety risk assessments under Risk module, and viral clearance validation packages under Change Control with linked audit trail. ICH Q5A records typically retained for the lifetime of the product line plus regulatory minimums.

Biotech often grows faster than traditional pharma, with frequent technology transfers (academic → biotech → CDMO → commercial). The eQMS must support phased rollout: research / preclinical (lighter QMS), clinical (Phase 1-3 GMP), commercial (full GMP). Module scope grows: starts with Documents + Training + Risk; adds CAPA, Audits, Change at clinical; adds Events / OOS / complaints at commercial. Tenant data carries forward across phases. Multi-vertical eQMS that scale from clinical to commercial without re-platforming serve biotech better than fixed-tier products.

Complere covers the QMS layer for biotech including cell + gene therapy programmes: Documents, CAPA, Audits, Controlled Change, Risk Assessments, Events, LMS. ICH Q5A risk records and viral safety assessments operate under the Risk module. Cell-bank document records under Documents with audit trail. Per-patient batch records (autologous CGT) require integration with specialised CGT platforms — Complere supports REST and GraphQL APIs for this. End-to-end vein-to-vein chain-of-custody requires a dedicated CGT platform alongside the eQMS.

Biotech sponsors typically use CDMOs for clinical and commercial manufacturing, especially in cell + gene therapy. Per ICH Q10 and EU GMP Chapter 7, sponsor and CDMO operate under written quality agreements defining who approves changes, releases batches, investigates deviations, and reports to regulators. The sponsor’s eQMS must support per-CDMO scoping, audit-trail visibility into CDMO records (where contractually permitted), and inbound deviation / CAPA / change-control evidence from CDMO sites. See the CDMO buyer’s guide for the inverse perspective.

Biotech residency demands depend on market: US-only biotech may not require non-US residency, but EU clinical / commercial requires EU GDPR-compliant data residency; India-based biotech (especially for export) faces India DPDP; UAE / KSA / GCC growing markets have local sovereignty mandates; China clinical / commercial requires China PIPL. Biotech CDMOs serving global sponsors face the union of all client jurisdictions. Per-customer regional residency (Complere’s full-stack per-region tenant) avoids the multi-tenant cross-region risk other platforms manage contractually.

List modules in scope (Documents, CAPA, Audits, Change, Training, Risk, Events, Suppliers, plus CGT platform integration if applicable). User counts, sites, regions, integrations (ERP, LIMS, MES, cell-processing platforms, apheresis). Validation depth (full CSV pack vs templates). Regulatory frameworks (ICH Q5A-Q5E, Q6B, Q9, Q10, EU Annex 1, EU Annex 2, Part 211, Part 600/610, Part 1271). Residency mandates per market. Send the same RFP to each vendor; compare on validation evidence, ICH Q5 alignment, residency, and 3-year TCO.